Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?

Pfizer's stock surged nearly 14% after striking a deal with the Trump administration, committing to significant drug price reductions and a $70 billion investment in U.S. innovation and manufacturing in exchange for a three-year exemption from pharmaceutical tariffs. This agreement alleviated major regulatory concerns regarding tariffs and Most Favored Nation (MFN) pricing for Pfizer and the broader pharmaceutical industry, prompting gains across other large drugmakers. While the company faces future challenges like patent expirations and COVID product uncertainty, the deal, combined with its strong oncology pipeline and attractive valuation (8.7x forward P/E, 7% dividend yield), positions Pfizer as a potential long-term hold, reducing a significant overhang.

Analysis

Pfizer's (PFE) recent deal with the Trump administration has materially de-risked the company's outlook, addressing major investor concerns around tariffs and Most Favored Nation (MFN) pricing. The agreement, which prompted a nearly 14% stock price increase, involves Pfizer lowering certain drug prices and committing $70 billion to U.S. investments in exchange for a three-year tariff exemption. This positive regulatory development is balanced against significant operational headwinds. On one hand, Pfizer's non-COVID business shows strength, with revenues from new and acquired products growing approximately 15% in the first half of 2025, and a robust oncology franchise, bolstered by the Seagen acquisition, projecting a 6% revenue CAGR from 2025-2030. On the other hand, the company faces a steep revenue cliff from declining COVID product sales, which fell from $56.7 billion in 2022 to an estimated $11 billion in 2024, and a significant loss-of-exclusivity period for key drugs between 2026 and 2030. Despite these challenges, Pfizer's financial position appears compelling; the stock trades at an attractive 8.70 forward P/E ratio, well below the industry's 15.93, and offers a dividend yield of approximately 7%. Furthermore, consensus earnings estimates for 2025 and 2026 have recently been revised upward, suggesting confidence in the company's ability to manage costs and drive bottom-line growth.

Key Decisions for Investors

• Given the stock's attractive valuation at an 8.70 forward P/E, a high dividend yield of approximately 7%, and the removal of a significant regulatory overhang, investors with a long-term horizon could view the current price as a compelling entry point.
• Investors should closely monitor the execution of Pfizer's strategy to offset the major 2026-2030 patent cliff through its oncology pipeline and the successful integration of acquisitions like Seagen and Metsera, as this is critical to sustaining long-term growth.
• While the drug pricing deal provides a positive catalyst, the investment thesis must balance this against persistent uncertainty in COVID-product sales and the $1 billion revenue impact from the IRA's Medicare Part D redesign.